Kevin Spain, a director at Doximity (DOCS), recently bought 775,000 shares. The buy came to a total cost of just over $20 million, and represents a new stake for the director.
The move comes as another director sold nearly 4.3 million shares, netting over $105 million. While that may sound extreme, the company just went public last week. Full insider data isn’t available yet, but it still appears substantial in its initial post-IPO period.
Doximity operates a cloud-based digital platform for medical professionals, to help coordinate and organize healthcare data. Shares are up about 10 percent from their IPO price of $50, but well off their peak trading price of $65.
- 25-Year-Old Prodigy Reveals Secret to Soaring Stocks
“Old school” folks might be skeptical of listening to financial advice from someone
half their age, but this stock whiz beat out 15,000 experts to claim #1 title.
The company went public at a time of profitability, and coming off a hot year of growth, with earnings up 188 percent and revenue up 83 percent. The company also sports a solid 24 percent profit margin.
Action to take: It’s a bit early to tell on any trading patterns in shares, but the company plays to some strong long-term trends in healthcare and technology. That makes shares a worthwhile buy here, as the company still carries a small market cap that could grow far larger.
Because the company is so new to the markets, no options trade yet. That will change in a few weeks, and traders may have more data to find a reasonable trading pattern by then.
Disclosure: The author of this article has no position in the company mentioned here, but may make a trade after the next 72 hours. The author receives no compensation from any of the companies mentioned in this article.